has earned tentative approval from the U.S. Food and Drug Administration for its hypertension drug.The company expects a final approval for the 50 mg/12.5 mg and 100 mg/25 mg losartan potassium and hydrochlorothiazide tablets, a generic version of
Hyzaar tablets, once that drug's patent expires in April 2010.
Hyzaar's annual sales are about $542 million.
Teva's shares closed up 21 cents at $36.14 Wednesday.
This story was created through a joint venture between TheStreet.com and IRIS.